Book covid PCR test: 0207 0343301 | Clinical trials: 0800 023 4824 or 0207 0343341

Clinical trials specialists in the heart of London

Copyright © Heart Lung Centre Site Made With ♥️ By Gossh Expert 2xN

You can have a role in research that could change medicine forever.

Paid clinical research studies are being conducted at Heart Lung Centre to learn more about investigational medications that are not yet available to the public.

Are Clinical Trials safe?

This is a very important question. At Heart Lung Centre, all our trials are reviewed by an independent Research Ethics Committee, who ensure that our trials are as safe as possible. We are here to answer any questions.

 

Learn More

Do I get paid?

Our trials vary greatly in terms of time spent on the unit and the number of procedures performed. Once we have identified a suitable trial, we can inform you of the potential compensation for your participation.

 

Learn More

What facilities are there?

Whether you’re here for an hour or the whole day, we will endeavour to make your stay as comfortable as possible. The volunteer lounge will provide you with a space to pass the time pleasantly between assessments.

 

Why do you offer Clinical Trials?

Before a medication or new device for treatment of medical issues is available to the public, the Food and Drug Administration (FDA) must review and approve the medication or device for public use. The FDA does this to learn more about the product and make sure that it is effective and safe.

To get FDA approval, the company that makes the medication or device is required to conduct clinical research studies.

The companies ask people to volunteer for clinical research studies. In these studies, volunteers are given the investigational medication or device and are evaluated by study doctors and staff members.

After clinical research studies are completed, the pharmaceutical company submits the study information to the FDA. The FDA reviews this information and decides if the investigational medication or device can become available to the public.

VOLUNTEER REGISTRATION FORM 

Explore current trials to check eligibility and register

  • Asthma studies​

    Asthma Clinical Trials are to evaluate newly developed medications and new combinations of well-established medications for the treatment of asthma.

    For all studies, participants are paid for their time, travel and any inconvenience.

    Medications administered, trial or placebo would be in addition to a volunteer’s current medication(s).

    If you would like to find out more register your interest and we will be in touch. Or contact us on 0207 034 3341 or 0800 023 4824 or recruitment@heartlungcentre.com

    Current studies are detailed below.

  • Asthma Study D3250C00059

    This is a clinical trial to evaluate a newly developed anti-inflammatory medication for the treatment of Asthma against a placebo. The medication has been tested in previous clinical trials with volunteers with severe Asthma, no safety issues were reported and the medication was shown to significantly reduce exacerbation rates, improve lung function and symptoms.

    Any medication administered, trial or placebo would be in addition to your current medication(s).

    To take part in this study you:

    • Must have been diagnosed with Asthma for 12 months or more
    • Must be between the ages of 18 to 70
    • Must use preventative Asthma medication on a stable, daily basis to manage your Asthma
    • Must be a non-smoker or an ex-smoker
    • Must Not be, pregnant, lactating or trying to conceive with your partner. (If applicable)
    • Must Not be currently enrolled another Clinical Trial

     

    This study involves 11 to 13 visits to our central London clinic over 58 weeks. No over-night stays required.

    You will be paid up to £1650 (pro rata) for your time, and any inconvenience. Reasonable travel expenses will be reimbursed.

    If you believe you may be eligible to take part and would like to find out more, register your interest and we will be in touch. Or contact us to find out more on 0207 034 3341 or 0800 023 4824 or recruitment@heartlungcentre.com

    Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.

    REGISTER

  • Asthma Study D7552C00001

    This is arandomized, double-blinded, placebo-controlled clinical trial to assess the efficacy and safety of AZD5718. No safety or tolerability issues linked to AZD5718 have yet been discovered in previous studies on healthy individuals.

    In total, there will be 6 visits, plus a telephone call, over a period of up to 5 months.

    You will be dispensed the study medication which you will have to consume two tablets in the morning daily alongside your regular asthma medication for 12 weeks.

    You will also be asked to fill out an e-diary and conduct spirometry measurements at home. Full training will be provided for this. The e-diary and spirometry measurements are to take place twice daily – in the morning after medication and in the evening.

    The study includes one initial screening visit to assess your eligibility. This includes questions about your medical history, a physical assessment, vital signs, ECGs, Blood tests and Lung Function testing.

    If you are found to be suitable there will be a second screening visit, where you will undergo further lung function tests, vital signs and blood tests. You will also be issued, and taught how to use, an at home spirometer and your e-dairy.

    • You will be reimbursed for your Travel up to £50 for each visit.
    • You will also be compensated £50 per visit for your time and inconvenience (£350 in total for the whole study.)

     

    If you believe you may be eligible to take part and would like to find out more, register your interest and we will be in touch. Or contact us to find out more on 0207 034 3341 or 0800 023 4824 or recruitment@heartlungcentre.com

    Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.

    REGISTER

  • COPD studies​

    Chronic Obstructive Pulmonary Disease Clinical Trials are to evaluate newly developed medications and new combinations of well-established medications for the treatment of COPD.

    For all studies, participants are paid for their time, travel and any inconvenience.

    Medications administered, trial or placebo would be in addition to a volunteer’s current medication(s).

    If you believe you may be eligible to take part and would like to find out more, register your interest and we will be in touch. Or contact us to find out more on 0207 034 3341 or 0800 023 4824 or recruitment@heartlungcentre.com

    Current studies are detailed below.

  • COPD Study CLI – 06001AA1 – 04_05

    This is a clinical trial to evaluate a newly developed medication for the treatment of COPD - Chronic Obstructive Pulmonary Disease against a placebo. The CHF6001 Medication has been tested in previous trials with COPD volunteers. No safety issues have been reported in these studies and the medication has been well tolerated.

    Any medication administered, trial or placebo would be in addition to your current medications.

    To take part in this study you:

    • Must have been diagnosed with COPD for 12 months or more.
    • Must be aged 40 and above.
    • Must be a Smoker or an Ex-Smoker.
    • Must be using Inhaler(s) to manage your COPD.
    • Must have a history of COPD exacerbation(s) within the last 12 months.
    • Must Not be currently enrolled in another clinical trial.

     

    This study involves 6 to 7 short visits to our Central London clinic over 52 weeks. No over-night stays are required.

    You will be paid up to £1000, pro rata for your time, and any inconvenience. Reasonable travel expenses will be reimbursed.

    If you believe you may be eligible to take part and would like to find out more, register your interest and we will be in touch. Or contact us to find out more on 0207 034 3341 or 0800 023 4824 or recruitment@heartlungcentre.com

    Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.

    REGISTER

  • COPD Study KN-002

    This study is part 4 of a Phase I Randomized, Double-Blinded, Placebo-Controlled, 4-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KN-002 by Inhalation.

    The aim of this study is to assess the safety and tolerability of a single inhaled dose of KN-002 IP after repeat administration in subjects with COPD 

    KN-002 has anti-inflammatory properties which suggests it has therapeutic potential as a treatment for COPD.

    Participants will receive a dose of KN-002 or placebo via a dry powder inhaler (DPI) twice daily for 10 days. 

    In total there will be 15 visits which take place over a period of 1-2 months. 

    1 Screening visit + 13 daily visits in a row + 1 Follow-up.  

    5 Overnight stays (3Nights from day -1 to 3, and 2 Nights from day 10 to 12).

    On days that are no overnights (days 3-9), participants will be require to come into the clinic twice a day – once in the morning and evening.

    If you pass screening, you will be invited for check in visit and overnight stays. Screening period is 28 days max. Follow up is 1 week after final overnight visit.

    This study requires no consumption of alcohol, caffeinated tea, coffee, energy drinks or chocolate-containing containing from screening to end of study (2 weeks), as well as no grapefruit or grapefruit containing products, or Seville oranges for 14 days before randomization to end of study (4 weeks). 

    If legible and all study visits are completed, you will be compensated for your time and inconvenience for up to £3990. Travel expenses will also be reimbursed.   

    If you believe you may be eligible to take part and would like to find out more, register your interest and we will be in touch. Or contact us to find out more on 0207 034 3341 or 0800 023 4824 or recruitment@heartlungcentre.com

    Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.

    REGISTER

  • COPD Study GB43311

    This is a Phase 2 clinical trial to evaluate the safety and efficacy of astegolimab at different dosages compared to a placebo in patients diagnosed with COPD.

    Five clinical studies have been completed with astegolimab already. 583 patients of either asthma, COPD, atopic dermatitis, and covid 19 pneumonia and 109 healthy subjects have been exposed to at least one dose of astegolimab. The drug has been well tolerated with no safety issues.

    In total, there will be a maximum of 29 visits over up to 14 months, with an optional opportunity for this to extend an extra 17 visits that would add an additional 7 months. 

    There will be 1 Screening Visit, and once you are found to be suitable there will be up to 27 visits every 2 weeks for 1 year. This will be followed by a follow up visit. 

    At the screening visit your eligibility will be assessed. This will be done by filling in questionnaires, taking vital signs, urine, and blood samples, conducting lung function tests, X rays and ECGs, and collecting Medical History. There is also an optional sub study where your sputum will be collected also if you opt in.                                             

    If you are found eligible, you will move onto the treatment visits, where the same assessments will be completed alongside being dosed with the study drug or placebo. The dosing method is 2 Subcutaneous injections of the medication in either side of the abdomen. Treatment visits occurs every 2 weeks. If you are found eligible, you will move onto the treatment visits, where the same assessments will be completed alongside being dosed with the study drug or placebo. The dosing method is 2 Subcutaneous injections of the medication in either side of the abdomen. Treatment visits occurs every 2 weeks.

    You will be Reimbursed for your Travel for up to £50 for each visit.  This study does not reimburse for time. 

    If you believe you may be eligible to take part and would like to find out more, register your interest and we will be in touch. Or contact us to find out more on 0207 034 3341 or 0800 023 4824 or recruitment@heartlungcentre.com

    Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.

    REGISTER

  • Upcoming Trials

    We have several new studies coming in late 2023/early 2024. These include:

  • A study for patients with chronic cough

    A study for patients with chronic cough (with or without asthma/COPD). This will be a crossover study, meaning all participants will receive both active medication and placebo. It will consist of 8-10 over 3 months. No recent exacerbations are required, but asthma/COPD patients will require stable use of maintenance inhalers.

  • Asthma study that requires no recent exacerbations

    An asthma study that requires no recent exacerbations, but requires stable use of maintenance inhalers. It is a placebo-controlled study lasting around 2 months with 9 visits.

  • COPD study that will be using an exercise bike

    A COPD study that will be using an exercise bike. This will be a crossover study, meaning all participants will receive both active medication and placebo. It will consist of 8 visits over 4 months. No recent exacerbations are required, but it will require stable use of maintenance inhalers.

FAQ'S

If you want to know more about clinical trials or are considering participating in one, the following frequently asked questions describe the role of a patient and will help you understand this unique research program.

FAQ'S

Location

Explore beyond the Heart Lung Centre and discover Respiratory Clinical Trials and our hospital Queen Anne Street Medical Centre. Our state of the art facility offers a range of medical services, including consultants in different specialties, diagnostic tests and an operating theatre.

13-14 Fitzroy Square,
London, W1T 6AH

E: recruitment@heartlungcentre.com
P: 0800 023 4824
P: 0207 0343341

Give us a call or email us, we endeavour to answer all enquiries within 24 hours on business days.

We are open from 8am — 5pm week days.